Wolverine Trading’s Pacira BioSciences PCRX Stock Holding History

Wolverine Trading’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,400	Closed	-$401K	–	4772
2022 Q3	$401K	Buy	7,400 +2,900	+64%	+$161K	﹤0.01%	2862
2022 Q2	$264K	Buy	+4,500	New	+$295K	﹤0.01%	3210
2021 Q4	–	Sell	-4,500	Closed	-$255K	–	6569
2021 Q3	$255K	Buy	+4,500	New	+$259K	﹤0.01%	4962
2019 Q4	–	Sell	-8,100	Closed	-$324K	–	5047
2019 Q3	$324K	Sell	8,100 -3,300	-29%	-$132K	﹤0.01%	3087
2019 Q2	$496K	Sell	11,400 -300	-3%	-$12.7K	﹤0.01%	2722
2019 Q1	$445K	Sell	11,700 -1,000	-8%	-$39K	﹤0.01%	2907
2018 Q4	$540K	Buy	+12,700	New	+$593K	﹤0.01%	2550
2017 Q2	–	Sell	-29,600	Closed	-$1.36M	–	4791
2017 Q1	$1.36M	Buy	29,600 +7,600	+35%	+$328K	0.01%	1476
2016 Q4	$711K	Sell	22,000 -18,100	-45%	-$604K	﹤0.01%	2237
2016 Q3	$1.36M	Buy	40,100 +10,100	+34%	+$396K	0.01%	1596
2016 Q2	$1.14M	Buy	+30,000	New	+$1.47M	0.01%	1493

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wolverine Trading's PCRX Position: Q4 2022 in Review

Wolverine Trading sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 4,058 shares — an estimated $220K sold.

Wolverine Trading first reported a position in PCRX in Q3 2016 and held it in 3 quarters. The position peaked at $699K in Q3 2016. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

Wolverine Trading reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
Wolverine Trading sold 4,058 Pacira BioSciences shares in Q4 2022, an estimated $220K.
Wolverine Trading first reported a position in Pacira BioSciences in Q3 2016 and held it in 3 quarters.
Wolverine Trading's Pacira BioSciences position peaked at $699K in Q3 2016.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Wolverine Trading's 13F filing for Q4 2022, filed 14 Feb 2023.